IP Library Granted Patent US 8,765,764
Granted Patent B2
US 8,765,764 · App. 13/677,520 · Granted Jul 1, 2014

2-acylaminothiazole derivative or salt thereof

Inventors: Keizo Sugasawa (Tokyo, JP); Susumu Watanuki (Tokyo, JP); Yuji Koga (Tokyo, JP); Hiroshi Nagata (Tokyo, JP); Ryutaro Wakayama (Tokyo, JP); Fukushi Hirayama (Tokyo, JP); Ken-Ichi Suzuki (Tokyo, JP)
Assignee: Astellas Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,764
App. No.
13/677,520
Granted
Jul 1, 2014
Kind
B2
Abstract

A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

Claims (14)

1. A method for the treatment of thrombocytopenia in a subject in need thereof, the method comprising:

administering to a subject in need thereof therapeutically effective amount of a compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof,

wherein the thrombocytopenia in the subject is treated; and

wherein the thrombocytopenia is due to liver disease.

2. The method according to claim 1 , wherein the method comprises: administering the effective amount of the compound in an oral dosage form comprising the compound and a pharmaceutically acceptable carrier.

3. The method according to claim 2 , wherein the effective amount of the compound is a daily dosage of between about 0.01 and about 1 mg/kg.

4. The method according to claim 3 , wherein the method comprises:

administering the effective amount of the compound in the form of one or more tablets once daily.

5. The method according to claim 1 , wherein the method comprises:

administering the therapeutically effective amount of the compound to the subject having a depressed platelet level, wherein the platelet level in the subject is increased or recovered.

6. The method according to claim 1 , wherein the method comprises:

administering the therapeutically effective amount of the compound to the subject such that administration results in cell proliferation and production of mature megakaryocytes and platelets.

7. The method according to claim 1 , wherein the compound is:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2014
From: SUGASAWA, KEIZO; WATANUKI, SUSUMU; KOGA, YUJI; NAGATA, HIROSHI; OBITSU, KAZUYOSHI; WAKAYAMA, RYUTARO; HIRAYAMA, FUKUSHI; SUZUKI, KEN-ICHI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 031904/0279 →
CHANGE OF NAME Recorded Jan 7, 2014
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 031934/0251 →
Priority Claims (2)
JP 2002-10413 · Jan 18, 2002 · national
JP 2002-10447 · Jan 18, 2002 · national
Continuity (3)
Continuation 12615968 · Nov 10, 2009
Continuation 10500964
Related Publication 20130079351A1 · Mar 28, 2013